TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Rhea-AI Summary

TriSalus Life Sciences (Nasdaq: TLSI) researchers have received two prestigious JVIR Top Paper Awards for their study demonstrating the superior performance of the TriNav Infusion System in liver tumor treatment. The study, which will be honored at the 2025 Society for Interventional Radiology meeting in Nashville, received the JVIR Editor's Award for Distinguished Laboratory Investigation and the JVIR People's Choice Award for Most Downloaded Articles.

The research, conducted using a porcine liver tumor model, revealed significant improvements in therapeutic delivery:

• 117% increase in tumor penetration for lobar infusions (p=0.004)
• 39% increase in tumor penetration for selective infusions (p=0.032)
• Lobar infusions using TriNav showed equivalent tumor penetration to selective delivery using traditional microcatheters (p=0.497)

The study utilized machine learning algorithms to quantify tumor penetration at a millimeter scale, contributing to the evidence supporting Pressure-Enabled Drug Delivery's (PEDD) effectiveness in treating primary and metastatic liver cancers.

Positive

• TriNav showed 117% increase in tumor penetration for lobar infusions
• 39% improvement in selective infusions tumor penetration
• Recognition through two prestigious JVIR awards validates technology effectiveness
• Study demonstrates superior performance compared to traditional microcatheters

Negative

• None.

Insights

Medical Device Expert

The recognition of TriSalus' research with two prestigious JVIR awards represents significant validation for their Pressure-Enabled Drug Delivery™ (PEDD) technology. The study demonstrates 117% increased tumor penetration for lobar infusions and 39% increase for selective infusions versus traditional microcatheters - both statistically significant improvements (p=0.004 and p=0.032 respectively).

What's particularly noteworthy is that lobar infusions (treating larger areas) with TriNav achieved tumor penetration statistically equivalent to selective delivery using traditional microcatheters. This suggests potential workflow and procedural efficiency improvements without sacrificing therapeutic coverage. For interventional radiologists, this could mean simplified procedures while maintaining or improving outcomes.

The methodology using transgenic porcine models with millimeter-scale quantification via machine learning algorithms represents a sophisticated approach to demonstrating efficacy. The JVIR Editor's Award specifically recognizes research with potential to substantially impact the interventional radiology community, while the most-downloaded designation indicates strong practitioner interest.

For TriNav adoption, this peer recognition serves as important evidence-based validation that could accelerate clinical integration. The technology addresses a fundamental challenge in liver cancer treatment - getting therapeutic agents to penetrate tumor tissue effectively - which has historically treatment efficacy. This growing body of evidence positions TriSalus favorably in the competitive landscape of liver-directed therapies.

Oncology Expert

The superior penetration demonstrated by TriSalus' TriNav system addresses a critical challenge in liver cancer treatment. Traditional delivery methods often struggle with the high interstitial pressure within solid tumors, resulting in suboptimal therapeutic distribution. The 117% improvement in lobar infusions is particularly significant as it could potentially enable more effective treatment of multifocal or larger liver tumors.

From a clinical perspective, the finding that lobar TriNav infusions achieve equivalent tumor penetration to selective traditional microcatheter delivery has important implications. This could simplify treatment protocols while potentially reducing procedure time and costs, making advanced liver-directed therapies more accessible.

The validation comes from a realistic porcine liver tumor model with quantification through machine learning algorithms - a sophisticated approach that bridges the gap between bench research and clinical application. The recognition through these JVIR awards will likely increase awareness among interventional oncologists and radiologists who make treatment decisions.

While this study specifically examined glass microspheres (commonly used in radioembolization procedures), the delivery technology has broader implications for other liver-directed therapies including chemoembolization and immunotherapies. For TriSalus, which is developing an integrated approach combining delivery technology with immunotherapy, this validation of their delivery platform strengthens their overall therapeutic strategy for solid tumors.

DENVER--(BUSINESS WIRE)--

TriSalus Life Sciences^®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent publication, including the JVIR Editor’s Award for Distinguished Laboratory Investigation and the JVIR People’s Choice Award for Most Downloaded Articles. These awards will be presented at the 2025 Society for Interventional Radiology meeting in Nashville TN.

This peer-reviewed study, titled “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model” highlighted the superior performance of the TriNav Infusion System in delivering Glass Microspheres into liver tumors when compared to delivery with a traditional microcatheter. The model used a transgenically modified porcine with therapeutic delivery quantified using a machine learning algorithm which documented tumor penetration at a millimeter scale. The study was published in the Journal of Vascular and Interventional Radiology.

Key Study Findings:

• In lobar infusions TriNav increased tumor penetration by 117% (p=0.004)
• In selective infusions TriNav increased tumor penetration by 39% (p=0.032)
• Lobar infusions using a TriNav had tumor penetration that was statistically equivalent to selective delivery using a traditional MC (p=0.497)

2024 JVIR Top Paper Awards Received by TriSalus:

• 2023 JVIR EDITOR’S AWARD FOR DISTINGUISHED LABORATORY INVESTIGATION. Winning manuscripts are selected after a rigorous review of all JVIR articles published in the preceding year. The chosen articles represent research that may substantially impact the Interventional Radiology community at present or in the future
• 2024 PEOPLE’S CHOICE AWARDS – MOST DOWNLOADED ARTICLES: The People’s Choice Award recognizes articles that garner the most readership interest, measured by the number of downloads

These findings add to the growing body of clinical and real-world evidence supporting PEDD's ability to improve the delivery of therapeutic agents for patients with primary and metastatic liver cancers.

To read the full study, visit here.

About TriSalus Life Sciences
TriSalus Life Sciences^® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutic delivery to solid tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors as well as other solid tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of infusion into solid tumors. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to limit delivery to normal tissue, creating the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Early data generated in Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.

JVIR Top Paper awards - IR Quarterly, the interventional radiology magazine

View source version on businesswire.com: https://www.businesswire.com/news/home/20250306426417/en/

For Media Inquiries:

Jeremy Feffer, Managing Director

LifeSci Advisors

917.749.1494

jfeffer@lifesciadvisors.com

For Investor Inquiries:

James Young

SVP-Investor Relations/Treasurer

847.337.0655

james.young@trisaluslifesci.com

Source: TriSalus Life Sciences

FAQ

What were the key findings of TriSalus' (TLSI) liver tumor treatment study?

The study showed TriNav increased tumor penetration by 117% in lobar infusions and 39% in selective infusions compared to traditional microcatheters.

Which awards did TriSalus' (TLSI) research receive from JVIR in 2024?

The research received the JVIR Editor's Award for Distinguished Laboratory Investigation and the People's Choice Award for Most Downloaded Articles.

How was the effectiveness of TLSI's TriNav Infusion System measured in the study?

The study used machine learning algorithms to quantify tumor penetration at a millimeter scale in a transgenic porcine liver tumor model.

What is the significance of TriSalus' (TLSI) lobar infusion results compared to traditional methods?

TriNav's lobar infusions achieved tumor penetration statistically equivalent to selective delivery using traditional microcatheters, demonstrating comparable effectiveness.